Document is current

Article History

Accepted: 28 April 2024

First Online: 20 May 2024

Declarations

:

: The study was conducted in accordance with the Declaration of Helsinki and in adherence with the Good Clinical Practice guidelines, and it was approved by the institutional review board (as listed in the original research paper by Najarian et al. []). Informed consent was obtained from all patients before enrollment in the original study.

: Janssen Research & Development LLC, USA.

: HTJ, RV, MN, AG, JJP-R, and OA are employees of Janssen Research & Development, LLC (a Johnson & Johnson company), and hold stock in Johnson & Johnson. SG and PN were employees of Janssen Research & Development when the study was conducted; SG is currently employed by Regeneron, and PN by CSK Behring.

: Conception and design: SG, AR, PN, JJPR. Collection of data: SG, RV, PN. Data analysis and interpretation: HT, RV, PN, JJPR, OA. Manuscript writing: HT. Review and final approval of the manuscript: all authors. All authors are accountable for all aspects of the work.

: Not applicable.

: The software used in this work is provided in the Methodology section and parameters shared in the results section.

: Not applicable, as this is a modelling and simulation study.

: All data generated or analyzed during this study are included in this published article and its supplementary information files. The data sharing policy of Janssen Pharmaceutical Companies of Johnson & Johnson is available at . As noted on this site, requests for access to the study data can be submitted through the Yale Open Data Access (YODA) project site at .